SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 32.65+0.5%Jan 14 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Omer Shvili who wrote (169)3/26/1998 10:22:00 PM
From: Ariella  Read Replies (2) of 340
 
"Copaxone Slows Progression Of Disability, Reduces Relapses In MS"

TORONTO, ON -- March 18, 1998 - Research published in the current issue of Neurology shows that Copaxone(R) (glatiramer acetate for injection) can actually slow the progression of relapse-remitting Multiple Sclerosis (MS).

continued at link: pslgroup.com

Question: is this "new" news or so old that no one cares? It seems to me that such research ought to help this drug gain market share.

--Ariella
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News